公开(公告)号：US10799569B2

公开(公告)日：2020-10-13

申请号：US16552873

申请日：2019-08-27

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200255491A1

公开(公告)日：2020-08-13

申请号：US16851985

申请日：2020-04-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Valentina Goldfinger ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/47 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/725 ,  C07K7/06 ,  G01N33/574 ,  C12N5/0783 ,  C12N15/115 ,  C07K14/74 ,  C12N15/62

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10654903B2

公开(公告)日：2020-05-19

申请号：US16504126

申请日：2019-07-05

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Valentina Goldfinger ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/47 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/725 ,  C07K7/06 ,  G01N33/574 ,  C12N5/0783 ,  C07K14/74 ,  C12N15/115 ,  C12N15/62

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10377802B2

公开(公告)日：2019-08-13

申请号：US16233284

申请日：2018-12-27

Applicant: immatics biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Valentina Goldfinger ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/47 ,  C07K7/06 ,  C07K14/74 ,  A61K39/00 ,  C07K14/725 ,  C12N5/0783 ,  A61K38/17 ,  C07K16/28 ,  C07K16/30 ,  C12N15/115 ,  C12N15/62 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10238727B2

公开(公告)日：2019-03-26

申请号：US16153294

申请日：2018-10-05

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Müller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/395 ,  A61K39/00 ,  G01N33/68 ,  C07K14/47 ,  C07K14/725 ,  C12N15/115 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574 ,  A61K38/00

Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.

公开(公告)号：US12076381B2

公开(公告)日：2024-09-03

申请号：US17576185

申请日：2022-01-14

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

CPC classification number: A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C12N5/0636 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/5748 ,  G01N33/6848 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2319/00 ,  C12N2310/16 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N2570/00 ,  G01N2800/52

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11826409B2

公开(公告)日：2023-11-28

申请号：US17320938

申请日：2021-05-14

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68

CPC classification number: A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C12N5/0636 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/5748 ,  G01N33/6848 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2319/00 ,  C12N2310/16 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N2570/00 ,  G01N2800/52

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11111280B2

公开(公告)日：2021-09-07

申请号：US16851976

申请日：2020-04-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Valentina Goldfinger ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/47 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/725 ,  C07K7/06 ,  G01N33/574 ,  C12N5/0783 ,  C07K14/74 ,  C12N15/62 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10899806B2

公开(公告)日：2021-01-26

申请号：US16851985

申请日：2020-04-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Valentina Goldfinger ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/47 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/725 ,  C07K7/06 ,  G01N33/574 ,  C12N5/0783 ,  C07K14/74 ,  C12N15/115 ,  C12N15/62

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10597433B2

公开(公告)日：2020-03-24

申请号：US16504134

申请日：2019-07-05

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Valentina Goldfinger ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/47 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/725 ,  C07K7/06 ,  G01N33/574 ,  C12N5/0783 ,  C07K14/74 ,  C12N15/115 ,  C12N15/62

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.